P1188: PERSONALIZED TREATMENT ACCORDING TO BIOLOGICAL PROFILE IMPROVES OUTCOME OF NEWLY DIAGNOSED PATIENTS AFFECTED BY DIFFUSE LARGE B-CELL LYMPHOMA: A REAL-LIFE EXPERIENCE

por Guidetti, A., Pasquale, R., Dodero, A., Chiappella, A., Devizzi, L., Farina, L., Rusconi, C., Pennisi, M., Corradini, P.
Publicado 2022

P1174: THE COMBINATION OF QUALITATIVE AND QUANTITATIVE METABOLIC PARAMETERS PREDICTS PROGRESSION-FREE SURVIVAL IN PATIENTS WITH LARGE B-CELL LYMPHOMAS (LBCL) TREATED WITH ANTI-CD19...

por Dodero, A., Guidetti, A., Lorenzoni, A., Pizzamiglio, S., Argiroffi, G., Verderio, P., Chiappella, A., Bagnoli, F., Carniti, C., Pennisi, M., Alessi, A., Corradini, P.
Publicado 2022

High-dose chemotherapy followed by autologous transplantation may overcome the poor prognosis of diffuse large B-cell lymphoma patients with MYC/BCL2 co-expression

por Maura, F, Guidetti, A, Pellegrinelli, A, Dodero, A, Pennisi, M, Caprioli, C, Testi, A, Farina, L, Bolli, N, Devizzi, L F, Cabras, A, Corradini, P
Publicado 2017

Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma

por Dodero, A., Guidetti, A., Tucci, A., Barretta, F., Novo, M., Devizzi, L., Re, A., Passi, A., Pellegrinelli, A., Pruneri, G., Miceli, R., Testi, A., Pennisi, M., Di Chio, M. C., Matteucci, P., Carniti, C., Facchetti, F., Rossi, G., Corradini, P.
Publicado 2019